While personally “disappointed” about the election’s outcome, current FDA Commissioner Robert Califf, M.D., has laid out the ...

Researchers, public health and health care groups, advocates, industry, and the public must put tackling diet-related disease ...

Kennedy has been most vocal about the FDA, an agency that oversees nearly $3 trillion in medicines, food and tobacco products ...

FDA commissioner Robert Califf’s second term is anticipated to end in 2025, and all eyes are now on who will be the next to ...

The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s ...

Staff turnover is typical when a new administration comes in, and a significant number of FDA employees similarly considered ...

Food and Drug Administration commissioner Robert Califf said he was “disappointed” with the presidential election result and ...

Trump has promised he would allow Robert F. Kennedy Jr. to "go wild" on medicines, food, and health. With that, a radical antiestablishment medical movement with roots in past centuries could threaten ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination ...

At a cancer research event Tuesday, FDA Commissioner Robert Califf said he was “disappointed” with the election results and ...

Califf notes uncertainty but believes the FDA is at "peak performance." FDA commissioner Robert Califf’s second term is anticipated to end in 2025, and all eyes are now on who will be the next ...